Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 7OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Prostatic Neoplasms 291Carcinoma, Renal Cell 172Kidney Neoplasms 118Urinary Bladder Neoplasms 102Breast Neoplasms 70Neoplasms 64Melanoma 48Testicular Neoplasms 45Sarcoma 45Wilms Tumor 44Lung Neoplasms 42Ovarian Neoplasms 41Neuroblastoma 39Colonic Neoplasms 34Lymphoma, Non-Hodgkin 32Lymphoma 31Osteosarcoma 28Neoplasm Metastasis 28Carcinoma, Non-Small-Cell Lung 28Pancreatic Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Uterine Cervical Neoplasms 24Colorectal Neoplasms 23Carcinoma, Transitional Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Medulloblastoma 22Urethral Neoplasms 21Central Nervous System Neoplasms 21Carcinoma, Ovarian Epithelial 21Burkitt Lymphoma 21

Interventions

Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenoviridae Infections × Genitourinary × Clear all
NCT03384316 2020-09-09

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 18 charts
BreastGastrointestinalGenitourinaryThoracic

Adenoviridae Infections, Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡